Cargando…

Pandemic Perspective: Commonalities Between COVID-19 and Cardio-Oncology

Overlapping commonalities between coronavirus disease of 2019 (COVID-19) and cardio-oncology regarding cardiovascular toxicities (CVT), pathophysiology, and pharmacology are special topics emerging during the pandemic. In this perspective, we consider an array of CVT common to both COVID-19 and card...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Sherry-Ann, Zaharova, Svetlana, Mason, Peter, Thompson, Jonathan, Thapa, Bicky, Ishizawar, David, Wilkes, Erin, Ahmed, Gulrayz, Rubenstein, Jason, Sanchez, Joyce, Joyce, David, Kalyanaraman, Balaraman, Widlansky, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746643/
https://www.ncbi.nlm.nih.gov/pubmed/33344513
http://dx.doi.org/10.3389/fcvm.2020.568720
_version_ 1783624832512950272
author Brown, Sherry-Ann
Zaharova, Svetlana
Mason, Peter
Thompson, Jonathan
Thapa, Bicky
Ishizawar, David
Wilkes, Erin
Ahmed, Gulrayz
Rubenstein, Jason
Sanchez, Joyce
Joyce, David
Kalyanaraman, Balaraman
Widlansky, Michael
author_facet Brown, Sherry-Ann
Zaharova, Svetlana
Mason, Peter
Thompson, Jonathan
Thapa, Bicky
Ishizawar, David
Wilkes, Erin
Ahmed, Gulrayz
Rubenstein, Jason
Sanchez, Joyce
Joyce, David
Kalyanaraman, Balaraman
Widlansky, Michael
author_sort Brown, Sherry-Ann
collection PubMed
description Overlapping commonalities between coronavirus disease of 2019 (COVID-19) and cardio-oncology regarding cardiovascular toxicities (CVT), pathophysiology, and pharmacology are special topics emerging during the pandemic. In this perspective, we consider an array of CVT common to both COVID-19 and cardio-oncology, including cardiomyopathy, ischemia, conduction abnormalities, myopericarditis, and right ventricular (RV) failure. We also emphasize the higher risk of severe COVID-19 illness in patients with cardiovascular disease (CVD) or its risk factors or cancer. We explore commonalities in the underlying pathophysiology observed in COVID-19 and cardio-oncology, including inflammation, cytokine release, the renin-angiotensin-aldosterone-system, coagulopathy, microthrombosis, and endothelial dysfunction. In addition, we examine common pharmacologic management strategies that have been elucidated for CVT from COVID-19 and various cancer therapies. The use of corticosteroids, as well as antibodies and inhibitors of various molecules mediating inflammation and cytokine release syndrome, are discussed. The impact of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) is also addressed, since these drugs are used in cardio-oncology and have received considerable attention during the COVID-19 pandemic, since the culprit virus enters human cells via the angiotensin converting enzyme 2 (ACE2) receptor. There are therefore several areas of overlap, similarity, and interaction in the toxicity, pathophysiology, and pharmacology profiles in COVID-19 and cardio-oncology syndromes. Learning more about either will likely provide some level of insight into both. We discuss each of these topics in this viewpoint, as well as what we foresee as evolving future directions to consider in cardio-oncology during the pandemic and beyond. Finally, we highlight commonalities in health disparities in COVID-19 and cardio-oncology and encourage continued development and implementation of innovative solutions to improve equity in health and healing.
format Online
Article
Text
id pubmed-7746643
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-77466432020-12-19 Pandemic Perspective: Commonalities Between COVID-19 and Cardio-Oncology Brown, Sherry-Ann Zaharova, Svetlana Mason, Peter Thompson, Jonathan Thapa, Bicky Ishizawar, David Wilkes, Erin Ahmed, Gulrayz Rubenstein, Jason Sanchez, Joyce Joyce, David Kalyanaraman, Balaraman Widlansky, Michael Front Cardiovasc Med Cardiovascular Medicine Overlapping commonalities between coronavirus disease of 2019 (COVID-19) and cardio-oncology regarding cardiovascular toxicities (CVT), pathophysiology, and pharmacology are special topics emerging during the pandemic. In this perspective, we consider an array of CVT common to both COVID-19 and cardio-oncology, including cardiomyopathy, ischemia, conduction abnormalities, myopericarditis, and right ventricular (RV) failure. We also emphasize the higher risk of severe COVID-19 illness in patients with cardiovascular disease (CVD) or its risk factors or cancer. We explore commonalities in the underlying pathophysiology observed in COVID-19 and cardio-oncology, including inflammation, cytokine release, the renin-angiotensin-aldosterone-system, coagulopathy, microthrombosis, and endothelial dysfunction. In addition, we examine common pharmacologic management strategies that have been elucidated for CVT from COVID-19 and various cancer therapies. The use of corticosteroids, as well as antibodies and inhibitors of various molecules mediating inflammation and cytokine release syndrome, are discussed. The impact of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) is also addressed, since these drugs are used in cardio-oncology and have received considerable attention during the COVID-19 pandemic, since the culprit virus enters human cells via the angiotensin converting enzyme 2 (ACE2) receptor. There are therefore several areas of overlap, similarity, and interaction in the toxicity, pathophysiology, and pharmacology profiles in COVID-19 and cardio-oncology syndromes. Learning more about either will likely provide some level of insight into both. We discuss each of these topics in this viewpoint, as well as what we foresee as evolving future directions to consider in cardio-oncology during the pandemic and beyond. Finally, we highlight commonalities in health disparities in COVID-19 and cardio-oncology and encourage continued development and implementation of innovative solutions to improve equity in health and healing. Frontiers Media S.A. 2020-12-04 /pmc/articles/PMC7746643/ /pubmed/33344513 http://dx.doi.org/10.3389/fcvm.2020.568720 Text en Copyright © 2020 Brown, Zaharova, Mason, Thompson, Thapa, Ishizawar, Wilkes, Ahmed, Rubenstein, Sanchez, Joyce, Kalyanaraman and Widlansky. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Brown, Sherry-Ann
Zaharova, Svetlana
Mason, Peter
Thompson, Jonathan
Thapa, Bicky
Ishizawar, David
Wilkes, Erin
Ahmed, Gulrayz
Rubenstein, Jason
Sanchez, Joyce
Joyce, David
Kalyanaraman, Balaraman
Widlansky, Michael
Pandemic Perspective: Commonalities Between COVID-19 and Cardio-Oncology
title Pandemic Perspective: Commonalities Between COVID-19 and Cardio-Oncology
title_full Pandemic Perspective: Commonalities Between COVID-19 and Cardio-Oncology
title_fullStr Pandemic Perspective: Commonalities Between COVID-19 and Cardio-Oncology
title_full_unstemmed Pandemic Perspective: Commonalities Between COVID-19 and Cardio-Oncology
title_short Pandemic Perspective: Commonalities Between COVID-19 and Cardio-Oncology
title_sort pandemic perspective: commonalities between covid-19 and cardio-oncology
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746643/
https://www.ncbi.nlm.nih.gov/pubmed/33344513
http://dx.doi.org/10.3389/fcvm.2020.568720
work_keys_str_mv AT brownsherryann pandemicperspectivecommonalitiesbetweencovid19andcardiooncology
AT zaharovasvetlana pandemicperspectivecommonalitiesbetweencovid19andcardiooncology
AT masonpeter pandemicperspectivecommonalitiesbetweencovid19andcardiooncology
AT thompsonjonathan pandemicperspectivecommonalitiesbetweencovid19andcardiooncology
AT thapabicky pandemicperspectivecommonalitiesbetweencovid19andcardiooncology
AT ishizawardavid pandemicperspectivecommonalitiesbetweencovid19andcardiooncology
AT wilkeserin pandemicperspectivecommonalitiesbetweencovid19andcardiooncology
AT ahmedgulrayz pandemicperspectivecommonalitiesbetweencovid19andcardiooncology
AT rubensteinjason pandemicperspectivecommonalitiesbetweencovid19andcardiooncology
AT sanchezjoyce pandemicperspectivecommonalitiesbetweencovid19andcardiooncology
AT joycedavid pandemicperspectivecommonalitiesbetweencovid19andcardiooncology
AT kalyanaramanbalaraman pandemicperspectivecommonalitiesbetweencovid19andcardiooncology
AT widlanskymichael pandemicperspectivecommonalitiesbetweencovid19andcardiooncology